Guardant Health (GH) Set to Announce Quarterly Earnings on Thursday

Guardant Health (NASDAQ:GH) is anticipated to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.75) per share and revenue of $350.72 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Guardant Health Price Performance

Shares of GH stock opened at $170.73 on Tuesday. Guardant Health has a 1 year low of $74.55 and a 1 year high of $191.05. The firm has a fifty day moving average price of $169.71 and a 200-day moving average price of $131.00. The company has a market cap of $22.91 billion, a price-to-earnings ratio of -48.92 and a beta of 1.58.

Insiders Place Their Bets

In other news, insider Chris Freeman sold 63,605 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the sale, the insider directly owned 65,374 shares in the company, valued at $11,086,122.92. This trade represents a 49.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steve E. Krognes sold 6,674 shares of Guardant Health stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the transaction, the director owned 7,906 shares in the company, valued at approximately $1,389,400.44. This trade represents a 45.78% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 164,760 shares of company stock valued at $27,817,425. Insiders own 5.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on GH shares. BTIG Research lifted their target price on Guardant Health from $195.00 to $210.00 and gave the company a “buy” rating in a research report on Tuesday, October 27th. Royal Bank Of Canada boosted their price target on Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. UBS Group upped their price target on Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research report on Thursday, October 15th. Finally, Mizuho raised their price objective on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.00.

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.